Our mission

Develop therapies that improve healthspan for all people.

Learn more
About us

Arrive is a biotechnology company developing therapies for age-related diseases by applying cutting edge deep learning to complex biologic systems.

Who's involved

Arrive is a group of passionate experts from diverse fields and backgrounds. Our leadership includes Anuj Gaggar (CEO), Andrew Brack (Head of Biology), and Evan Szu (COO).

We work with a network of key advisors with insights from present and past work at leading drug development organizations like Jennifer King (Intellia) Eric Suba (Kaiser), Andrew Dahlem (Eli Lilly), Marc Berger (Pfizer), Stephen Eck (Macrogenics), Joe Nolan (Jaguar Gene Therapy) and others.

Our partners include Roche, FDA, EDB Singapore, Singapore General Hospital, and others.

Roche Logo
EDB Singapore Logo
Singapore General Hospital Logo
Founded in Silicon Valley, California


Offices in

San Francisco & Singapore


Arrive Head of Ageing Andrew Brack speaks at National Academy of Medicine meeting on Healthy Longevity.

Arrive Head of Aging Andrew Brack will speak at American Aging Association.

Evan Szu speaks at the Singapore Academy of Sciences.

Arrive is working with the FDA to establish standards for A.I. algorithms in pathology. Read the HTT pilot study paper.

Join Arrive

We are here to shape the future. We invite inquiries from exceptional drug development, biology and engineering talent.

COnnect with us
Arrive Team Diagram